

7/13
4.5.01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jian Ni et al.

Application Number: 09/227,854

Group Art Unit: 1647

Filed: January 11, 1999

Examiner: G. Draper

Title: **HUMAN CHEMOTACTIC CYTOKINE I**

Attny. Docket No. **PF210D**

TECH CENTER 1600/2900
APR 04 2001

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56(c)

Commissioner for Patents
Washington, D.C. 20231

SIR:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject application, Agent for Applicants hereby directs the Examiner's attention to reference B2 listed on the attached form PTO/SB/08A. A copy of reference B2 is enclosed.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.


04/03/2001 MABDI1 0000084 083425 09227854
02 FC:126 180.00 CH

Pursuant to 37 C.F.R. § 1.97(c)(2), since this Supplemental Information Disclosure Statement is filed after the mailing date of a First Office Action on the merits, the Patent and Trademark Office will consider the statement if the statement is accompanied by the fee as specified in 37 C.F.R. § 1.97(c)(2), and is filed before any of a final action under § 1.113, a notice of allowance under § 1.311, or an action which otherwise closes the prosecution in this application.

Accordingly, pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office is authorized to charge the required fee of \$180.00 to Human Genome Sciences, Inc., Deposit Account No. 08-3425. Applicants submit concurrently herewith, a Fee Transmittal, with appropriate fee(s). The Patent Office is further authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3425.

Respectfully submitted,

Date: April 2, 2001


Joseph J. Kenny (Reg. No. 43,710)
Agent for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone (301) 610-5800

Enclosures
MMW/JJK/RL/lcc

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2001

Fees are subject to annual revision.

APR 02 2001

Total amount of payment (\$ 570.00)

Complete if Known

1647 \$1

METHOD OF PAYMENT (CHECK ONE)

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

Deposit Account 08-3425

Number

Deposit Account Human Genome Sciences, Inc.
Name Charge Any Additional Fee Required
Under 37 CFR §§ 1.16 and 1.17 Applicant claims small entity status

See 37 CFR 1.27

 Payment Enclosed:
 Check Credit Card Money Order Other

Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425

FEE CALCULATION (CONTINUED)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Fee Fee Fee

Code (\$ Code (\$

105 130 205 65

Surcharge - late non-provisional filing fee or cover sheet

127 50 227 25

Surcharge - late provisional filing fee or cover sheet

139 130 139 130

Non-English specification

147 2,520 147 2,520

For filing a request for *ex parte* reexamination

112 920 112 920

Requesting publication of SIR prior to Examiner action

113 1,840 113 1,840

Requesting publication of SIR after Examiner action

115 110 215 55

Extension for reply within first month

116 390 216 195

Extension for reply within second month

117 890 217 445

Extension for reply within third month

118 1,390 218 695

Extension for reply within fourth month

128 1,890 228 945

Extension for reply within fifth month

119 310 219 155

Notice of Appeal

120 310 220 155

Filing a brief in support of an appeal

121 270 221 135

Request for oral hearing

138 1,510 138 1,510

Petition to institute a public use proceeding

140 110 240 55

Petition to revive -unavoidable

141 1,240 241 620

Petition to revive - unintentional

142 1,240 242 620

Utility issue fee (or reissue)

143 440 243 220

Design issue fee

144 600 244 300

Plant issue fee

122 130 122 130

Petitions to the Commissioner

123 50 123 50

Petitions related to provisional applications

126 180 126 240

Submission of Information Disclosure Statement

581 40 481 40

Recording each patent assignment per property (times number of properties)

146 710 246 355

Filing a submission after final rejection (37 CFR 1.129(a))

149 710 249 355

For each additional invention to be examined (37 CFR 1.129(b))

179 710 279 355

Request for Continued Examination (RCE)

169 190 169 900

Request for expedited examination of a design application

Other fee (specify):.....

Other fee (specify):.....

*Reduced by Basic Filing Fee Paid

Subtotal (3)

\$ 570.00

Subtotal (2) (\$ 0.00)

Submitted By

Complete (if applicable)

Name (Print/Type) Joseph J. Kenny

Registration No.: 43,710

Telephone

301-610-5800

Signature: *Joseph J. Kenny*

Date

4/2/01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.